Lifeward Ltd. — Form 8-K Summary
Filing date: October 27, 2026. This current report concerns an executive appointment, not quarterly or annual financial results.
Business context and key event
On October 26, Lifeward’s board appointed Ronen Tsimerman as chief financial officer, principal financial officer and principal accounting officer, effective November 1, 2026. He most recently served as CFO of Scopio Labs from August to October 2026 and previously served as CFO of IceCure Medical from 2017 to August 2026, among other finance roles.
Financial metrics and changes
The filing provides no revenue, profit, cash flow, margin, debt, liquidity or other operating or financial results. It does not quantify any financial impact from the appointment. Compensation amounts and terms disclosed are prospective arrangements, not reported expenses.
Compensation, outlook and other matters
- The contemplated employment agreement provides for gross monthly base salary of NIS 70,000, an annual performance-based bonus determined by the compensation committee and board, with a target of at least four monthly salaries, and a transaction bonus. Bonus terms are subject to the company’s renewed compensation policy and any required approvals.
- The agreement is subject to shareholder approval of the renewed compensation policy at the annual general meeting scheduled for October 30, 2026.
- Either party may terminate with three months’ notice; the notice period increases to four months for either party following a change in the company’s CEO, including appointment of a permanent CEO.
- Lifeward also entered into its standard indemnification, insurance and exculpation agreement with Mr. Tsimerman. The filing states that he has no disclosed family relationship with company directors or officers and identifies no other appointment-related arrangements or reportable related-party transactions.
Important facts for investors to verify
- Whether shareholders approve the renewed compensation policy at the October 30, 2026 annual general meeting.
- Whether the CFO appointment takes effect as scheduled on November 1 and the final employment agreement terms, including the transaction bonus.
- Subsequent filings for financial results or material developments; this 8-K contains no financial performance or liquidity information.